KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major

Vaccine

Volumn 27, Issue 9, 2009, Pages 1306-1316

  Bhaumik, Suniti ^a   Basu, Rajatava ^a   Sen, Subha ^a   Naskar, Kshudiram ^a   Roy, Syamal ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

DNA vaccination; Parasitic protozoan; Th1 Th2 cells

Indexed keywords

CD4 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 4; KINETOPLAST DNA; KINETOPLASTID MEMBRANE PROTEIN 11; KINETOPLASTID MEMBRANE PROTEIN 11 DNA VACCINE; MEMBRANE PROTEIN; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; DRUG MECHANISM; EXPRESSION VECTOR; GENE; KMP 11 GENE; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE IMMUNITY; PRIORITY JOURNAL; SPECIES DIFFERENCE; TH1 CELL; TH2 CELL; VACCINE PRODUCTION;

ANIMALS; CLONING, MOLECULAR; CYTOKINES; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; PROTOZOAN PROTEINS; RNA, PROTOZOAN;

EID: 59849102406     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.12.053     Document Type: Article

References (50)

1. Dumonteil E, McMahon-Pratt D, Price V. Report on the fourth TDR/IDRI meeting on second-generation vaccines against leishmaniasis, 1 to 3 May 2001. Universidad Autonoma de Yucatan, Yucatan, Mexico. Document TDR/PDR/LEISH/VAC/01.1; 2001.
2. Aguilar-Be I., da Silva Zardo R., Paraguai de Souza E., Borja-Cabrera G.P., Rosado-Vallado M., Mut-Martin M., et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73 2 (2005) 812-819
3. + T cell responses and protection against Leishmania major infection. J Exp Med 195 12 (2002) 1565-1573
4. Olobo J.O., Anjili C.O., Gicheru M.M., Mbati P.A., Kariuki T.M., Githure J.I., et al. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania major surface glycoprotein (gp63). Vet Parasitol 60 3-4 (1995) 199-212
5. Rafati S., Salmanian A.H., Taheri T., Vafa M., and Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19 25-26 (2001) 3369-3375
6. Sjölander A., Baldwin T.M., Curtis J.M., Bengtsson K.L., and Handman E. Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 16 20 (1998) 2077-2084
7. Ghosh A., Zhang W.W., and Matlashewski G. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20 1-2 (2001) 59-66
8. Gurunathan S., Prussin C., Sacks D.L., and Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 4 12 (1998) 1409-1415
9. Rachamim N., and Jaffe C.L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J Immunol 150 (1993) 2322-2331
10. Melby P.C., Yang J., Zhao W., Perez L.E., and Cheng J. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 69 8 (2001) 4719-4725
11. Stäger S., Smith D.F., and Kaye P.M. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 165 12 (2000) 7064-7071
12. Heinzel F.P., Schoenhaut D.S., Rerko R.M., Rosser L.E., and Gately M.K. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 177 5 (1993) 1505-1509
13. Sypek J.P., Chung C.L., Mayor S.E., Subramanyam J.M., Goldman S.J., Sieburth D.S., et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 177 6 (1993) 1797-1802
14. Mattner F., Magram J., Ferrante J., Launois P., Di Padova K., Behin R., et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 26 7 (1996) 1553-1559
15. Belkaid Y., Mendez S., Lira R., Kadambi N., Milon G., and Sacks D. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 165 2 (2000) 969-977
16. Sacks D., and Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2 11 (2002) 845-858
17. Park A.Y., Hondowicz B.D., and Scott P. IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol 165 2 (2000) 896-902
18. Launois P., Gumy A., Himmelrich H., Locksley R.M., Röcken M., and Louis J.A. Rapid IL-4 production by Leishmania homolog of mammalian RACK1-reactive CD4(+) T cells in resistant mice treated once with anti-IL-12 or -IFN-gamma antibodies at the onset of infection with Leishmania major instructs Th2 cell development, resulting in nonhealing lesions. J Immunol 168 9 (2002) 4628-4635
19. + T cells which are NK1.1-. Eur J Immunol 25 12 (1995) 3298-3307
20. Engwerda C.R., Murphy M.L., Cotterell S.E., Smelt S.C., and Kaye P.M. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur J Immunol 28 2 (1998) 669-680
21. Satoskar A.R., Rodig S., Telford III S.R., Satoskar A.A., Ghosh S.K., von Lichtenberg F., et al. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immunol 30 3 (2000) 834-839
22. Satoskar A., Bluethmann H., and Alexander J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect Immun 63 12 (1995) 4894-4899
23. Alexander J., Carter K.C., Al-Fasi N., Satoskar A., and Brombacher F. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30 10 (2000) 2935-2943
24. Stäger S., Alexander J., Kirby A.C., Botto M., Rooijen N.V., Smith D.F., et al. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med 9 10 (2003) 1287-1292
25. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174 11 (2005) 7160-7171
26. Kaye P.M., Curry A.J., and Blackwell J.M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 146 8 (1991) 2763-2770
27. Kemp M., Kurtzhals J.A., Bendtzen K., Poulsen L.K., Hansen M.B., Koech D.K., et al. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun 61 3 (1993) 1069-1073
28. Kurtzhals J.A., Hey A.S., Jardim A., Kemp M., Schaefer K.U., Odera E.O., et al. Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients. Clin Exp Immunol 96 3 (1994) 416-421
29. Miralles G.D., Stoeckle M.Y., McDermott D.F., Finkelman F.D., and Murray H.W. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 62 3 (1994) 1058-1063
30. + cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infect Immun 75 12 (2007) 5956-5966
31. Stebeck C.E., Beecroft R.P., Singh B.N., Jardim A., Olafson R.W., Tuckey C., et al. Kinetoplastid membrane protein-11 (KMP-11) is differentially expressed during the life cycle of African trypanosomes and is found in a wide variety of kinetoplastid parasites. Mol Biochem Parasitol 71 1 (1995) 1-13
32. Basu R., Roy S., and Walden P. HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J Infect Dis 195 9 (2007) 1373-1380
33. Mukhopadhyay R., and Madhubala R. Antileishmanial activity and modification of hepatic xenobiotic metabolizing enzymes in golden hamster by 2(3)-tert-butyl-4-hydroxyanisole following infection with Leishmania donovani. Biochem Pharmacol 47 2 (1994) 253-256
34. Awasthi A., Mathur R., Khan A., Joshi B.N., Jain N., Sawant S., et al. CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. J Exp Med 197 8 (2003) 1037-1043
35. Rafati S., Gholami E., Hassani N., Ghaemimanesh F., Taslimi Y., Taheri T., et al. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine 25 21 (2007) 4159-4169
36. Chang J., Cho J.H., Lee S.W., Choi S.Y., Ha S.J., and Sung Y.C. IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells. J Immunol 172 5 (2004) 2818-2826
37. Grogan J.L., Mohrs M., Harmon B., Lacy D.A., Sedat J.W., and Locksley R.M. Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immunity 14 3 (2001) 205-215
38. Jardim A., Tolson D.L., Turco S.J., Pearson T.W., and Olafson R.W. The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex. J Immunol 147 10 (1991) 3538-3544
39. Pakpour N., Zaph C., and Scott P. The central memory CD4+ T cell population generated during Leishmania major infection requires IL-12 to produce IFN-gamma. J Immunol 180 12 (2008) 8299-8305
40. Santos W.R., de Lima V.M., de Souza E.P., Bernardo R.R., Palatnik M., and Palatnik de Sousa C.B. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21 1-2 (2002) 30-43
41. Schüler T., Qin Z., Ibe S., Noben-Trauth N., and Blankenstein T. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 189 5 (1999) 803-810
42. Karp C.L., el-Safi S.H., Wynn T.A., Satti M.M., Kordofani A.M., Hashim F.A., et al. In vivo cytokine profiles in patients with kala-azar: marked elevation of both interleukin-10 and interferon-γ. J Clin Invest 91 (1993) 1644-1648
43. Melby P.C., Andrade-Narvaez F.J., Darnell B.J., Valencia-Pacheco G., Tryon V.V., and Palomo-Cetina A. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun 62 3 (1994) 837-842
44. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168 8 (2002) 3992-4000
45. Huber M., Timms E., Mak T.W., Röllinghoff M., and Lohoff M. Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice. Infect Immun 66 8 (1998) 3968-3970
46. Da-Cruz A.M., Conceição-Silva F., Bertho A.L., and Coutinho S.G. Leishmania-reactive CD4+ and CD8+ T cells associated with cure of human cutaneous leishmaniasis. Infect Immun 62 6 (1994) 2614-2618
47. Gurunathan S., Stobie L., Prussin C., Sacks D.L., Glaichenhaus N., Iwasaki A., et al. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J Immunol 165 2 (2000) 915-924
48. Kurzawa H., Wysocka M., Aruga E., Chang A., Trinchieri G., and Lee W.M.F. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Res 58 (1998) 491-499
49. Lee K., Overwijk W.W., O'Toole M., Swiniarski H., Restifo N.P., Dorner A.J., et al. Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. J Interferon Cytokine Res 20 6 (2000) 589-596
50. Orange J.S., Wolf S.F., and Biron C.A. Effects of IL-12 on the response and susceptibility to experimental viral infections. J Immunol 152 (1994) 1253